In 2023, the AUS Executive Committee approved a task force to undertake the effort of adding medications to the Micromedex database for off-label use in ocular inflammatory diseases. This task force was led by Drs. Robert Swan and Bob Moorthy and we'd like to announce some important updates from their work:
Micromedex recently approved the following medications and off-label uses:
- Tocilizumab for adult uveitis
- Adalimumab for adult PUK
- Rituximab for adult scleritis
Data has also been submitted and is being considered by Micromedex for the following:
- Tocilizumab for pediatric uveitis
- Rituximab for OCP
- Infliximab for PUK
Many insurances use the Micromedex compendium to decide whether or not they will approve a medication for use in patients. This task force has been instrumental in expanding access to medications for our patients, as it also is a resource for finding primary literature supporting the drug's off-label use in certain conditions. We want to recognize the leaders and members of this task force for their important work in lowering barriers to help obtain effective treatment for our patients!
AUS Micromedex Task Force Members
Robert Swan, MD (co-chair)
Bob Moorthy, MD (co-chair)
Laura Kopplin, MD, PhD
Christopher Conrady, MD, PhD
Joan Lee, DO
Jennifer Cao, MD
Caroline Minkus, MD
